Ark Therapeutics extends PER.C6 licensing deal with Crucell

By E. Janene Geiss

Philadelphia, Jan. 18 - Crucell NV said Wednesday that Ark Therapeutics Group plc has decided to renew its PER.C6 technology licensing agreement.

Under the renewed agreement, the companies have negotiated research and commercial terms for Ark's development and manufacture of gene-based medicine using Crucell's PER.C6 technology, according to a company news release.

Financial details were not disclosed.

Crucell is a Leiden, The Netherlands, biotechnology company focused on developing vaccines and antibodies that prevent and treat infectious diseases, including Ebola, influenza, malaria, West Nile virus and rabies.

Ark is a London-based specialty health care group with a focus on vascular disease and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.